AZT: Prolonging Life But Not Stopping Death

Helquist, Michael
March 1987
Advocate;3/3/87, Issue 467, p23
Reports that the medical advisers of the U.S. Food and Drug Administration have recommended in 1987 the licensing of AZT for sale to a restricted group of patients with AIDS or severe ARC. Initial results of studies on AZT; Benefits from taking AZT; Researchers' concerns about side effects.


Related Articles

  • New Report on AZT. Helquist, Michael // Advocate;1/17/89, Issue 516, p30 

    Reports on a study indicating that azidothymidine (AZT) can reverse the deterioration in mental and cognitive capabilities often experienced by individuals with AIDS or AIDS-related complex. Support for anecdotal reports on the benefits of the antiviral drug; Details of the study.

  • Timing of AZT. M.O.R. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p139 

    Warns against the use of zidovudine monotherapy in newly diagnosed HIV patients. Drugs which could be combined with zidovudine to increase anti-HIV activity; Factors on which decisions about when to initiate treatment are usually based.

  • Drug Combo Update. Helquist, Michael // Advocate;10/29/85, Issue 432, p23 

    Reports on the effectiveness of using two drugs, isoprinosine and ribavirin to treat AIDS and AIDS-related complex. Existing practice of administering the drugs to patients; Mechanism of treatment; Implications for AIDS treatment.

  • AIDSSPEAK.  // Body Politic;Dec86, Issue 133, p15 

    Presents the definition of several terms related to AIDS. ARC; AZT; HIV; PWA.

  • Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life. Abrams, Donald I.; Steinhart, Corklin; Frascino, Robert; Abrams, D I; Steinhart, C; Frascino, R // International Journal of STD & AIDS;Oct2000, Vol. 11 Issue 10, p659 

    To evaluate the effect of epoetin alfa on the quality of life (QOL) of HIV-infected patients in the community setting, 221 anaemic (haemoglobin < or = 11 g/dl) HIV-positive patients from community-based treatment centres and physicians' offices were treated with epoetin alfa (100-300 units/kg...

  • Combining acyclovir and zidovudine for AIDS patients. Donaldson Jr., Robert M.; Berkowitz, Henry D. // Cortlandt Forum;7/25/95, Vol. 8 Issue 7, p92 

    Discusses the use of acyclovir and zidovudine in the treatment of AIDS patients. Reduction in the initial development of opportunistic infections; Prolonged survival in patients with HIV; Side effects of a combination of zidovudine and acyclovir.

  • A Comparison of Itraconazole Versus Fluconazole as Maintenance Therapy for AIDS-Associated Cryptococcal Meningitis. Saag, Michael S.; Cloud, Gretchen A.; Graybill, J. Richard; Sobel, Jack D.; Tuazon, Carmelita U.; Johnson, Philip C.; Fessel, W. Jeffrey; Moskovitz, Bruce L.; Wiesinger, Barbara; Cosmatos, Dennis; Riser, Laura; Thomas, Carolynn; Hafner, Richard; Dismukes, William E. // Clinical Infectious Diseases;2/1/1999, Vol. 28 Issue 2, p291 

    This study was designed to compare the effectiveness of fluconazole vs. itraconazole as mainte-nance therapy for AIDS-associated cryptococcal meningitis. HIV-infected patients who had been successfully treated (achieved negative culture of CSF) for a first episode of cryptococcal meningitis ...

  • No significant side effects for minority patients who take AZT.  // AIDS Patient Care & STDs;Jun96, Vol. 10 Issue 3, p185 

    Details the effectiveness of AZT in the treatment of African-American patients with AIDS. Determination of racial or ethnic differences in the tolerance of AZT; Absence of significant side effects of the drug.

  • NEWSFRONT: NEW YORK.  // Advocate;12/22/87, Issue 488, p26 

    Reports that the New York State Health Department will use a multimillion-dollar fund to buy the drug AZT for low-income people with AIDS or AIDS-related complex (ARC).


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics